Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 597 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Taking on DNA repair to tackle cancer November 5, 2021 Studies Delve Deep into the Protein Machinery of Cancer Cells November 4, 2021 Can a Biopsy Make My Cancer Spread? March 18, 2021 NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted... April 13, 2022 Load more HOT NEWS Child Cancer Patient And His Dad Have A Little Fun When... Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness World Cancer Research Day: Celebrating Progress in Treating and Caring for... Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom...
